Botanix Grows Sofdra Prescriptions Amid $45M Capital Raise and New API Supplier

Sofdra Prescription Growth Hits New High Despite Revenue Dip

Botanix Pharmaceuticals Limited (ASX:BOT) saw total prescriptions shipped (TRx) for its dermatology product Sofdra increase 5% in Q3 FY26 to 26,684, capping the quarter with a March record of 10,653 shipments. This steady growth comes even as net revenue fell 24% quarter-on-quarter to $6.9 million, a decline the company attributes to the annual deductible reset affecting roughly half of privately insured Americans under 65. Gross sales held steady at $38.0 million, indicating strong underlying demand despite the temporary reimbursement headwinds.

The deductible reset, which requires patients to meet new insurance deductibles each calendar year, depressed Botanix's average gross-to-net (GTN) yield to 18% in Q3 from 24% in Q2, though GTN improved from 16% to 19% over the quarter and is expected to rebound further in Q4. This dynamic reflects the seasonal nature of US health insurance and reimbursement patterns rather than any product-specific weakness.

Capital Raise and Cash Position Strengthened for Growth

To support its growth and operational needs, Botanix completed a $45 million capital raising comprising a $40 million two-tranche placement and a $5 million underwritten security purchase plan. At quarter-end, the company held $22.1 million in cash, including $14.1 million from the first tranche of the placement. Subsequent to the quarter, Botanix received an additional $28.7 million from the second tranche and SPP, bringing pro forma cash to approximately $50.8 million. This infusion bolsters the company’s balance sheet ahead of anticipated growth phases and supply chain investments.

The capital raise follows earlier announcements and investor interest in Botanix’s strategy to expand Sofdra’s market penetration and operational capabilities. The fresh funds provide the company with runway to manage working capital efficiently and invest in manufacturing and fulfilment infrastructure, as well as to pursue strategic growth initiatives.

API Supply Agreement Renegotiated and New Supplier Onboarded

Botanix successfully renegotiated its active pharmaceutical ingredient (API) supply agreement with Kaken Pharmaceutical, deferring two payments of approximately US$7.5 million each originally due in April 2026 and January 2027 until later years, smoothing cash flow and extending the next anticipated API purchase to December 2027. This move aligns with the company’s current inventory position of around $34.5 million in API, deemed sufficient for interim growth needs.

Complementing this, Botanix has agreed to terms with PPL Pharma Solutions Riverview LLC (Piramal) to serve as an alternate API supplier. Piramal’s US manufacturing site is strategically positioned to mitigate the impact of upcoming US pharmaceutical tariffs, which could impose a 15% levy on Sofdra finished products imported from Canada. The alternate supply arrangement is expected to reduce costs of goods sold by 25% to 40% once fully onboarded, with benefits anticipated to materialise progressively through 2028.

These supply chain developments are critical for Botanix’s cost control and margin improvement efforts, and they dovetail with the company’s broader strategy to enhance its proprietary Botanix Fulfilment Platform, which has demonstrated strong insurance approval rates and patient compliance metrics.

Fulfilment Platform and M&A Potential

The Botanix Fulfilment Platform remains a core asset, enabling scalable addition of new products with minimal start-up costs and improved margins through direct pharmacy consignment. The platform’s success in driving prescription fill rates roughly 2.5 times the industry standard positions Botanix well for potential mergers and acquisitions. The company is actively assessing acquisition targets that could benefit commercially from integration into this platform, leveraging its existing sales force embedded in dermatology practices.

Botanix’s commercial momentum and supply chain rationalisation efforts follow earlier capital raising announcements and supply deferral agreements, which collectively reinforce the company’s capacity to execute on its growth plans and navigate market headwinds such as the deductible reset and tariff risks Botanix Signs Term Sheet with Second API Supplier and Botanix Defers Key API Purchases.

Financial Discipline Amid Growing Operating Costs

Operating cash outflow rose 35% to $23.3 million in Q3 FY26, primarily driven by the $9.7 million API purchase in March. Excluding this, operating cash outflow actually declined 21% to $13.6 million, reflecting disciplined cost control and the absence of one-off regulatory fees such as the prior quarter’s FDA PDUFA payment. Staff costs also decreased due to timing differences in bonus payments rather than structural changes.

Botanix’s loan facility with Kreos Capital remains in place, with $29.2 million drawn of a $43.8 million facility, providing additional financial flexibility. The company estimates it has approximately 1.6 quarters of funding available based on current operating cash outflows and available financing, though the recent capital raise substantially improves its liquidity runway.